Navigation Links
VIVIMIND(TM) granted certificate of free sale as food supplement in Italy - Premarket notification filed in the U.S.
Date:7/16/2009

ECUBLENS, SWITZERLAND, July 16 /PRNewswire-FirstCall/ - BELLUS Health (International) Limited, a wholly owned subsidiary of BELLUS Health Inc. (BELLUS Health, TSX: BLU), today announced that the Italian Ministry of Health has granted a certificate of free sale for VIVIMIND(TM) (homotaurine) as a food supplement. A certificate of free sale in Italy permits the commercial sale of the product in that country. This certificate opens up means by which to pursue marketing and sales authorization in the other member states of the European Union.

VIVIMIND(TM) is a patented, amino acid, present in some species of algae, to support cognitive function and memory. VIVIMIND(TM) is now available in Canada. Recently published data in a peer-reviewed journal show that homotaurine slows the loss of volume in the hippocampus, a region of the brain associated with memory, and has a beneficial effect on cognition(1).

U.S. Regulatory Update

With respect to the United States, OVOS Natural Health Inc., a wholly owned subsidiary of BELLUS Health Inc., has filed a premarket notification of a New Dietary Ingredient for homotaurine with the U.S. Food and Drug Administration, and is pursuing mandatory associated regulatory activities to obtain marketing approval for homotaurine as a dietary supplement.

About BELLUS Health Inc.

BELLUS Health is a global health company focused on the development and commercialization of products to provide innovative health solutions to address critical unmet needs.

To Contact BELLUS Health Inc.

For additional information on BELLUS Health and its drug development programs, please call the Canada and United States toll-free number 1-877-680-4500 or visit the Web Site at www.bellushealth.com.

(1) S. Gauthier, P. S. Aisen, S. H. Ferris, D. Saumier, A. Duong,

D. Haine, et al. (2009). Effect of Tramiprosate in Patients with

Mild-to-Moderate Alzheimer's Disease: Exploratory Analyses of the MRI

Sub-group of the Alphase Study. Journal of Nutrition, Health and Aging,

Volume 13, Number 6/June 2009, 550-557.

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond BELLUS Health Inc.'s control. Such risks include but are not limited to: the impact of general economic conditions, general conditions in the pharmaceutical and/or nutraceutical industry, changes in the regulatory environment in the jurisdictions in which the BELLUS Health Group does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation, that actual results may vary once the final and quality-controlled verification of data and analyses has been completed, as well as other risks disclosed in public filings of BELLUS Health Inc. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. These statements speak only as of the date made and BELLUS Health Inc. is under no obligation and disavows any intention to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation. Please see the Annual Information Form of BELLUS Health Inc. for further risk factors that might affect the BELLUS Health Group and its business.

CONTACT: Michelle Stein, Specialist, Corporate Communications, (450) 680-4573, mstein@bellushealth.com


'/>"/>
SOURCE BELLUS HEALTH INC.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM)
2. Fate Therapeutics Granted Exclusive License By The Regents of the University of California to Stem Cell Modulators for Osteo-Regeneration
3. A Random Act of Kindness Changes a Familys Life Forever as Alexzander Prados Wish to Walk is Granted at Abilities Expo
4. Impliant Granted Two New U.S. Patents and Successfully Defends European Patent Opposition Case
5. Vision Pharma Is Granted Motion for Judgment
6. Acclarent, Inc. Granted Key Patent Covering Balloon Sinuplasty(TM) Technologies
7. Lilly Granted Preliminary Injunction to Prevent Launch of Generic Raloxifene
8. Hahnemann University Hospital Granted Surgical Fellowship Training Program for Pelvic Floor Disorders
9. Tolera Therapeutics Granted Orphan Drug Designation for Organ Transplant Rejection Drug
10. Rib-X Granted Key Antibiotic Patent in China
11. MonoSol Rx Granted U.S. Article of Manufacture Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... METTLER ... ions found in power plant water and steam. , Chlorides and sulfates cause ... boilers, leading to extensive maintenance and unplanned shutdowns. Monitoring these ions at low ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Executives, Staff & Clients of ... for the Toys for Tots Literacy Campaign at their Semi-Annual Graduation and Fundraiser Event ... billion, the U.S. ranks at number 14 internationally in literacy. Statistically, a direct relation ...
(Date:3/28/2017)... ... March 28, 2017 , ... A ... achieve the “perfect smile.” The National Association of Dental Laboratories (NADL) is informing ... should be aware of when utilizing dental laboratories and technicians that create these ...
(Date:3/28/2017)... Santa Monica, CA (PRWEB) , ... March 28, ... ... expert, Dr. Carson Liu of SkyLex Advanced Surgical, Inc. is thrilled to offer ... newest gastric balloon procedure, and this procedure adds to SkyLex Advanced Surgical’s ...
(Date:3/28/2017)... ... March 28, 2017 , ... The Lice ... Atlantic City March 13-16, was a busy spot this year. Liz Solovay and ... strategies for preventing outbreaks among camp communities during the upcoming 2017 camping season. ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... , March 27, 2017 The ... digital health and data analytics company, signed a ... for improving healthcare delivery in the region. ... for Global Health Research and Technology (BIGHEART) at ... on several topics related to healthcare IT and ...
(Date:3/27/2017)... Summary This report provides ... and its partnering interests and activities since 2010. Description ... in-depth insight into the partnering activity of one of the ... reports are prepared upon purchase to ensure inclusion of the ... The report will be delivered in PDF format within 1 ...
(Date:3/27/2017)... 27, 2017  A recent study at Shriners Hospitals ... hospitals in the country dedicated to the treatment of ... concluded that the Surfacide Helios ® UV-C Disinfection ... reducing bacterial pathogens not killed by the EVS (manual) ... the American Burn Association,s 49th Annual Meeting in ...
Breaking Medicine Technology: